Abstract 83P
Background
VG2025 is a non-attenuated HSV-1 Oncolytic virus (OV) with the payloads IL-12, IL-15, and IL-15Ra and a Carcinoembryonic Antigen (CEA) specific promoter for ICP27. Here, we reported a first-in-human, open-label study to evaluate the safety and efficacy of VG2025 in patients (pts) with advanced solid tumors that progressed after standard care, conducted in China.
Methods
3+3 Dose escalation design with 5 dose levels as intratumoral injections on days 1 and 15 of each 28-day cycle. Preliminary safety, efficacy (per RECIST v1.1), PK, viral shedding and the immune biomarkers were analyzed.
Results
The preliminary findings of this study were presented at ASCO 2023, here we present updated results of additional dose levels. As of Aug 8, 2023, 14 pts received doses of 1.0x10ˆ8 PFU (n=3), 2.0x10ˆ8 PFU (n=3), 4.0x10ˆ8 PFU (n=3), and 6.0x10ˆ8 PFU (n=5) of each cycle. The longest duration of treatment was more than 11 cycles and the treatment is still ongoing. There were 11 males and 3 females with a median age of 51.5 (41-74). 57.1% were PD(L)1 refractory, 28.6% had 2 prior lines of therapy, and 64.3% had 3 or more prior lines of therapy. The mean CEA level was 29.1 (normal range of 0-5 μg/L). Tumor types included 4 CRC, 2 Duodenal adenocarcinoma, 2 HCC, 2 Pancreatic cancer, 1 NSCLC, 1 ICC, 1 NEC and 1 Neuroendocrine cancer. No DLTs were observed. The incidence of TRAEs and Gr≥3 TRAEs were 92.9% and 50.0%, with fever being the most common TRAE. 4 pts had 7 SAEs, which were unrelated to VG2025. No TRAEs led to dose reduction or treatment discontinuation. No pts had positive viral shedding. Of 9 evaluable pts, the ORR was 22.2% (with 2 PRs: 1 ICC pt and 1 NEC pt) and the DCR was 77.8%. The PR pts showed meaningful reductions in CEA levels. Tumor shrinkage was also observed in non-injected lesions, demonstrating an abscopal effect. Nanostring analysis of paired biopsies from the PR pts demonstrated upregulation of integrin signaling pathway, antigen-presenting MHC (HLA-DQA1 and HLA-DRB1) and chemokine receptor (CMKLR1) genes, and activation of CD8+ T cells.
Conclusions
Monotherapy with VG2025 demonstrated activity with a well-tolerant safety profile in pts with advanced solid tumors that progressed after standard of care therapy.
Clinical trial identification
NCT05477849.
Editorial acknowledgement
Legal entity responsible for the study
Shanghai Virogin Biotech Co., Ltd.
Funding
Has not received any funding.
Disclosure
Y. Shen, T. Liang: Financial Interests, Personal, Coordinating PI: Virogin. S. Rahimian, A. Qin, Y. Qiu, Q. Tan, R. Zhao: Financial Interests, Personal, Full or part-time Employment: Virogin. All other authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract